Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study

M. Bertolotti, A. Nobili, C. Mussi, P.M. Mannucci, M. Tettamanti, L. Pasina, F. Salerno, G.R. Corazza, M. Marcucci, G. Grignani, M. Bernardi, M. Barbagallo, M.D. Cappellini, G. Fabio, D. Mari, P.D. Rossi, E. Miceli, G. Murialdo, A. Marra, M.B. SecchiM. Carbone, M.R. Meroni, P. Gallo, M. Rubino, G. Martucci, M. Serra, M. Pala, M.R. Rizzo, F. Fontana, C. Bracco, S. Fargion, F. Peyvandi, A. Tedeschi, V. Monzani, V. Savojardo, C. Folli, M.M.F. Salerno, C.L. Balduini, G. Bertolino, S. Di Carlo, G.B. Bianchi, G. Vendemiale, A. Mirijello, A. Maresca, M. Serra, G.P. Martino, S. Messina, M. Cattaneo, C. Bussolino, M. Arcopinto, A.M. Marra, A. Ballestrero

Research output: Contribution to journalArticlepeer-review


Background: Older patients are prone to multimorbidity and polypharmacy, with an inherent risk of adverse events and drug interactions. To the best of our knowledge, available information on the appropriateness of lipid-lowering treatment is extremely limited. Aim: The aim of the present study was to quantify and characterize lipid-lowering drug use in a population of complex in-hospital older patients. Methods: We analyzed data from 87 units of internal medicine or geriatric medicine in the REPOSI (Registro Politerapie della Società Italiana di Medicina Interna) study, with reference to the 2010 and 2012 patient cohorts. Lipid-lowering drug use was closely correlated with the clinical profiles, including multimorbidity markers and polypharmacy. Results: 2171 patients aged >65 years were enrolled (1057 males, 1114 females, mean age 78.6 years). The patients treated with lipid-lowering drugs amounted to 508 subjects (23.4%), with no gender difference. Atorvastatin (39.3%) and simvastatin (34.0%) were the most widely used statin drugs. Likelihood of treatment was associated with polypharmacy (≥5 drugs) and with higher Cumulative Illness Rating Scale (CIRS) score. At logistic regression analysis, the presence of coronary heart disease, peripheral vascular disease, and hypertension were significantly correlated with lipid-lowering drug use, whereas age showed an inverse correlation. Diabetes was not associated with drug treatment. Conclusions: In this in-hospital cohort, the use of lipid-lowering agents was mainly driven by patients’ clinical history, most notably the presence of clinically overt manifestations of atherosclerosis. Increasing age seems to be associated with lower prescription rates. This might be indicative of cautious behavior towards a potentially toxic treatment regimen. © 2017, Springer International Publishing Switzerland.
Original languageEnglish
Pages (from-to)311-319
Number of pages9
JournalDrugs and Aging
Issue number4
Publication statusPublished - Apr 2017


  • antilipemic agent
  • atorvastatin
  • beta adrenergic receptor blocking agent
  • calcium channel blocking agent
  • colestyramine
  • dipeptidyl carboxypeptidase inhibitor
  • diuretic agent
  • ezetimibe
  • fenofibrate
  • fluindostatin
  • mevinolin
  • omega 3 fatty acid
  • pravastatin
  • proton pump inhibitor
  • rosuvastatin
  • sartan derivative
  • simvastatin
  • aged
  • Article
  • cohort analysis
  • cumulative scale
  • dyslipidemia
  • female
  • hospital patient
  • human
  • hypertension
  • ischemic heart disease
  • major clinical study
  • male
  • peripheral vascular disease
  • polypharmacy
  • prescription
  • primary prevention
  • priority journal
  • quantitative analysis
  • secondary prevention
  • hospitalization
  • prevalence
  • statistical model
  • very elderly
  • Aged
  • Aged, 80 and over
  • Female
  • Hospitalization
  • Humans
  • Hypolipidemic Agents
  • Logistic Models
  • Male
  • Polypharmacy
  • Prevalence


Dive into the research topics of 'Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study'. Together they form a unique fingerprint.

Cite this